HHS secretary nominee Robert F. Kennedy Jr. answered nearly all of the Senate Finance Committee Democrats’ detailed drug pricing questions with a simple response that he will “follow the law,” declining to show his hand on whether he might seek changes to the Inflation Reduction Act’s Medicare drug price negotiation language or to CMS’ implementation policies, modify ongoing CMS Innovation Center demonstrations or revamp FDA’s treatment of the Orange book, according to his written responses posted Friday (Jan. 31) following...